中东和非洲共济失调市场，按类型（脊髓小脑共济失调、共济失调-毛细血管扩张症、发作性共济失调和其他（多系统萎缩 (MSA)））、产品（治疗和诊断）、剂型（固体、液体和其他）、给药途径（口服、肠胃外和其他）、患者类型（成人、儿童和老年人）、最终用户（医院、诊所、家庭医疗保健和其他）、分销渠道（直接招标、零售销售和其他）划分 - 行业趋势和预测到 2029 年。
中东和非洲
税法病的日益流行增加了市场的需求。 用于改善保健服务的保健开支不断增加也促进了市场的增长。 在这一关键时期,主要市场参与者高度关注产品推出和产品审批. 此外,政府和监管机构正在通过产品批准支持市场参与者,因为产品激增。
由于市场参与者的崛起和先进产品的可获性,中东和非洲税收市场在预测的年份正在增长。 与此同时,制造商还参与研发活动,在市场上推出新产品。 税法治疗领域越来越多的研究以及酒精和药物消费的增加,预计将进一步推动市场增长。 然而,一些发展中国家在诊断该疾病方面遇到的困难和缺乏基因检测设施,可能妨碍中东和非洲税制市场在预测期间的增长。
越来越多的保健支出和市场参与者的战略举措可能给市场带来加强治疗的机会。 然而,一些与批准药品和产品以及从各公司召回产品有关的严格规则和条例预计将对市场增长构成挑战。
预计中东和非洲税收市场将在2022至2029年的预测期间获得市场增长。 数据桥市场研究分析认为,在2022至2029年的预测期内,市场正在增长,CAGR为4.6%,预计到2029年将达到518.38万美元,而2021年为377.38万美元。
|
报表计量 |
细节 |
|
预测期 |
2022至2029年统计 |
|
基准年 |
2021 |
|
历史年代 |
2020 |
|
数量单位 |
收入(千美元),定价(美元) |
|
覆盖部分 |
按类型(螺旋管阿塔克西亚 阿塔克西亚-特兰吉克塔西亚临时Ataxia等(多系统萎缩症),产品(治疗和诊断),剂量表(Solid、液体等),管理路线(Oral、pareeral等),病人类型(Adult、儿童和老年病),最终用户(医院、诊所、家庭保健等),分销渠道(Direct招标、零售等) |
|
涵盖国家 |
南非、沙特阿拉伯、阿联酋、埃及、以色列、科威特、中东其他地区和非洲 |
|
覆盖的市场玩家 |
Novartis AG、Merck KGaA、Aurobindo Pharma、Pfize公司、Sanofi、Teva制药工业有限公司、Viatris公司、Sun制药工业有限公司、Lupin、Cipla公司等 |
市场定义
Ataxia是一类影响协调,平衡,和口语的紊乱症的术语. 任何人都可能受到影响,但患税症的人往往在平衡,行走,说话,吞咽,以及需要高度控制的任务方面遇到困难,如写作,吃吃,和视觉. 准确的症状及其严重性因一个人的税法类型而异.
Ataxia通常是由脑部被叫作"脑"的一部分损伤而来,但也可能由神经系统的其他部分被损伤而来. 这种损伤可能是MS(多发性硬化症)等内在状况的一部分,也可能由头部受伤,大脑缺氧,或长期过度饮用酒精所造成. 遗传性ataxia是由可能或不会受到影响的家庭成员所传递的有缺陷的基因引起的.
中东和非洲动态
司机
- 税务治疗领域的快速研究
据报道,税法存在各种风险因素。 因此,为了减少与之相关的风险因素和症状,正在税法治疗方面进行各种研究。 一些政府资金也开始用于处理市场上的各类税法. 在税法治疗领域进行的各种快速研究可能有助于在预测的时期内推动市场,并预计为同样目的进行的研究和开发将出现重大增长。
- 酗酒和吸毒率上升
酒精和药物使用率的上升会导致维生素B-12,维生素E和胺缺乏. 体内缺乏这些养分被认为是引起厌食症的主要原因. 体内缺乏维生素E会导致神经系统问题,如协调动作困难(ataxia)和口语困难(dysarthria),腿部失去反射力(四肢下垂),极限神经病(peripheral neurosy)失去感觉,这导致各种类型的ataxia. 越来越多的人和年轻人饮用过量的酒精和药物,也增加了受到各种税法影响的机会。 预计这将推动中东和非洲税收市场的增长。
机会
- 保健支出增加
随着各国人民可支配收入的增加,全世界的保健支出已经增加。 此外,为满足人口需求,政府机构和保健组织正在采取主动行动,加快保健支出。 保健支出的上升同时有助于保健环境改善其治疗税务疾病的设施,因为近年来这种疾病非常普遍。
此外,主要市场参与者采取的战略举措将为2022-2029年预测期的税制市场提供结构完整性和未来机会。
限制/挑战
然而,一些发展中国家在诊断该疾病方面的困难和缺乏遗传检测设施,将阻碍中东和非洲税收市场的增长。 此外,严格的规则和条例将进一步挑战预测期的市场。
这份中东和非洲税收市场报告详细介绍了最近的新发展、贸易条例、进出口分析、生产分析、价值链优化、市场份额、国内和地方市场参与者的影响、分析新收入区、市场监管变化、战略市场增长分析、市场规模、类别市场增长、应用优势和支配地位、产品批准、产品推出、地域扩张、市场技术创新等方面的机会。 为了获得更多有关中东和非洲税收市场的信息,请与数据桥市场研究公司联系,以获得一份分析员简报;我们的团队将帮助你作出知情的市场决定,以实现市场增长。
COVID-19之后的影响中东和非洲 税收市场
COVID-19对市场产生了积极影响. 流行病期间的封锁和隔离使疾病管理和药物坚持情况复杂化。 因此,各种治疗药物在世界人口中普遍增加。 因此,这种流行病对这一市场产生了积极影响。
最近的发展
- 2021年11月,萨诺菲宣布公司已经与卡德蒙完成了收购. 这有助于公司扩大产品组合,并通过各种非专利药品增加收入。
中东和非洲市场范围
中东和非洲税收市场分为类型、产品、剂量形式、管理路线、病人类型、最终用户和分销渠道。 这些部门的增长将有助于你分析这些行业的微弱增长部门,并为用户提供宝贵的市场概况和市场见解,以便作出战略决定,确定核心市场应用。
类型
- Spinocerebellar 税制
- 阿塔克西亚-特兰吉克塔西亚
- 税制
- 其他(多系统萎缩)
根据类型,中东和非洲税市被划分为:脊椎动物税(spinocerebellar ataxia),克特兰基克塔西亚(ataxia-telangiectasia),克特兰基克塔西亚(spisosodic ataxia)等(多系统萎缩(MSA)).
产品
- 诊断
- 治疗
根据产品,中东和非洲税收市场被划分为治疗和诊断。
剂量表单
- 固态
- 液体
- 其他人员
根据剂量形式,中东和非洲税市被分割成固体,液体等.
.行政路线
- 口头
- 家长
- 其他人员
根据行政路线,中东和非洲税收市场被划分为口头市场、上级市场等。
患者类型
- 成人
- 儿童
- 老年病
根据病人类型,中东和非洲税收市场分为成人、儿童和老年病。
结束用户
- 医院
- 诊所
- 家庭保健
- 其他人员
在最终用户的基础上,中东和非洲税收市场分为医院、诊所、家庭保健等。
分发频道
- 直接招标
- 零售
- 其他人员
根据分销渠道,中东和非洲税收市场分为直接招标、零售等。
中东和非洲 税收市场 区域分析/见解
分析中东和非洲税收市场,并按国家、类型、产品、剂量形式、管理路线、病人类型、最终用户和分销渠道提供市场规模的见解和趋势。
该地区覆盖的一些国家有南非,沙特阿拉伯,阿联酋,埃及,以色列,科威特,中东其他地区和非洲. 在市场份额和收入方面,南非预计将主宰中东和非洲税收市场,并将在预测期间继续繁荣其支配地位。 这是由于该地区税制盛行,而快速的研究发展正在推动市场的发展.
报告的国家部分还提供了个别市场影响因素和影响市场当前和未来趋势的市场监管变化。 数据点,如新的和替换销售、国家人口统计、疾病流行病学和进出口关税,是用来预测个别国家市场情况的一些主要指针。 此外,在对国家数据进行预测分析的同时,还考虑到中东和非洲品牌的存在和可得性,以及它们因当地和国内品牌竞争激烈而面临的挑战和销售渠道的影响。
竞争性景观和中东和非洲 市场 共享分析
中东和非洲税收市场竞争环境提供了竞争者的详细信息。 详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、全球存在、生产地点和设施、生产能力、公司优势和弱点、产品推出、产品宽度和广度以及应用优势。 上述数据点仅涉及公司对中东和非洲税收市场的关注。
在中东及非洲税制市场运营的一些主要角色有:诺华AG,默克克克克克克加A,Aurobindo Pharma.,普菲泽公司,萨诺菲,特瓦制药工业有限公司,维亚特里斯股份有限公司,太阳制药工业有限公司,鲁平,西普拉股份有限公司等.
研究方法
数据收集和基准年分析使用具有大样本规模的数据收集模块。 利用市场统计和连贯一致的模式分析和估计市场数据。 此外,市场份额分析和主要趋势分析是市场报告的主要成功因素. DBMR研究小组使用的关键研究方法是数据三角化,涉及数据挖掘、数据变量对市场的影响分析以及初级(行业专家)验证。 除此之外,数据模型包括供应商定位网格、市场时间线分析、市场概况和指南、公司定位网格、公司市场份额分析、计量标准、中东和非洲对区域以及供应商份额分析。 如有进一步调查,请致电分析员。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA ATAXIA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 EPIDEMIOLOGY
5 PIPELINE ANALYSIS
6 MIDDLE EAST & AFRICA ATAXIA MARKET: REGULATORY SCENARIO
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA
7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS
7.1.3 RISE IN ALCOHOL AND DRUG USAGE
7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE
7.2 RESTRAINTS
7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE
7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE EXPENDITURE
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 STRINGENT RULES AND REGULATIONS
7.4.2 PRODUCT RECALL
8 MIDDLE EAST & AFRICA ATAXIA MARKET, BY TYPE
8.1 OVERVIEW
8.2 SPINOCEREBELLAR ATAXIAS
8.2.1 TYPE 3
8.2.2 TYPE 2
8.2.3 TYPE 1
8.2.4 OTHERS
8.3 ATAXIA-TELANGIECTASIA
8.4 EPISODIC ATAXIA
8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA))
9 MIDDLE EAST & AFRICA ATAXIA MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 PHARMACOTHERAPY
9.2.1.1 STIFFNESS/SPASTICITY
9.2.1.1.1 GABAPENTIN
9.2.1.1.2 LEVODOPA
9.2.1.1.3 OTHERS
9.2.1.2 GAIT AND TREMORS
9.2.1.2.1 VARENICLINE
9.2.1.2.2 RILUZOLE
9.2.1.2.3 AMANTADINE
9.2.1.2.4 OTHERS
9.2.1.3 ANTI-OXIDANTS
9.2.1.3.1 N‐ACETYLCYSTEINE
9.2.1.3.2 SELEGILINE
9.2.1.3.3 DEHYDROEPIANDROSTERONE
9.2.1.3.4 VITAMIN E
9.2.1.4 NON ANTI-OXIDANTS
9.2.1.4.1 ERYTHROPOIETIN
9.2.1.4.2 DEFERIPRONE
9.2.1.4.3 RESVERATROL
9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS
9.2.1.5 ANTI-ARRHYTHMIC AGENTS
9.2.1.5.1 AMIODARONE
9.2.1.5.2 PROPAFENONE
9.2.1.5.3 FLECAINIDE
9.2.1.5.4 IBUTILIDE
9.2.1.6 ANTI-CARDIAC FAILURE
9.2.1.6.1 BENAZEPRIL
9.2.1.6.2 LISINOPRIL
9.2.1.6.3 CAPTOPRIL
9.2.1.6.4 ENALAPRIL
9.2.1.6.5 FOSINOPRIL
9.2.1.6.6 MOEXIPRIL
9.2.1.6.7 OTHERS
9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS
9.2.1.7.1 BIGUANIDES (METFORMIN)
9.2.1.7.2 SULFONYLUREAS
9.2.1.7.2.1 GLIPIZIDE
9.2.1.7.2.2 GLIMEPIRIDE
9.2.1.7.2.3 GLYBURIDE
9.2.1.7.2.4 OTHERS
9.2.1.7.3 THIAZOLIDINEDIONES
9.2.1.7.4 MEGLITINIDES
9.2.2 LIFESTYLE THERAPY
9.2.2.1 PHYSICAL THERAPY
9.2.2.2 SPEECH THERAPY
9.2.2.3 PALLIATIVE CARE
9.2.2.4 OTHERS
9.2.3 SUPPORTIVE DEVICES
9.2.3.1 WALKING AIDS
9.2.3.2 WHEELCHAIRS
9.2.3.3 OTHERS
9.3 DIAGNOSTICS
9.3.1 IMAGING TEST
9.3.1.1 MRI SCAN
9.3.1.2 OTHERS
9.3.2 BLOOD TEST
9.3.3 GENETIC TESTING
10 MIDDLE EAST & AFRICA ATAXIA MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 SOLID
10.2.1 TABLETS
10.2.2 CAPSULES
10.2.3 OTHERS
10.3 LIQUIDS
10.3.1 INJECTION
10.3.2 SOLUTIONS
10.3.3 OTHERS
10.4 OTHERS
11 MIDDLE EAST & AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.4 OTHERS
12 MIDDLE EAST & AFRICA ATAXIA MARKET, BY PATIENT TYPE
12.1 OVERVIEW
12.2 ADULT
12.2.1 MALE
12.2.2 FEMALE
12.3 CHILD
12.4 GERIATRIC
13 MIDDLE EAST & AFRICA ATAXIA MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 MIDDLE EAST & AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.3.1 HOSPITAL PHARMACY
14.3.2 RETAIL SHOP
14.3.3 ONLINE PHARMACY
14.4 OTHERS
15 MIDDLE EAST & AFRICA ATAXIA MARKET, BY GEOGRAPHY
15.1 MIDDLE EAST AND AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 U.A.E
15.1.4 ISRAEL
15.1.5 EGYPT
15.1.6 KUWAIT
15.1.7 REST OF MIDDLE EAST AND AFRICA
16 MIDDLE EAST & AFRICA ATAXIA MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 SELECT MEDICAL CORPORATION
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 NOVARTIS AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 AMNEAL PHARMACEUTICALS LLC.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLI
18.4.5 RECENT DEVELOPMENT
18.5 UPSTREAM REHABILITATION INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 COMPANY SHARE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 PRIORY
18.6.1 COMPANY SNAPSHOT
18.6.2 COMPANY SHARE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 ACORDA THERAPEUTICS, INC.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 ADVERUM BIOTECHNOLOGIES, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 APOTEX INC.
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 ATI PHYSICAL THERAPY
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 AUROBINDO PHARMA
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 BANNER HEALTH
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 BIOHAVEN PHARMACEUTICALS
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 BIOVISTA
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 CIPLA INC.
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 DESIGN THERAPEUTICS, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 INTRABIO
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
18.18 LUPIN.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
18.19 MATRIX BIOMED
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 MERCK KGAA
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
18.21 REATA PHARMACEUTICALS, INC.
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENT
18.22 RETROTOPE INC.
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.23 SANOFI
18.23.1 COMPANY SNAPSHOT
18.23.2 REVENUE ANALYSIS
18.23.3 PRODUCT PORTFOLIO
18.23.4 RECENT DEVELOPMENT
18.24 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.24.1 COMPANY SNAPSHOT
18.24.2 REVENUE ANALYSIS
18.24.3 PRODUCT PORTFOLIO
18.24.4 RECENT DEVELOPMENT
18.25 SUTTER HEALTH
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENTS
18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.26.1 COMPANY SNAPSHOT
18.26.2 REVENUE ANALYSIS
18.26.3 PRODUCT PORTFOLIO
18.26.4 RECENT DEVELOPMENT
18.27 VIATRIS INC.
18.27.1 COMPANY SNAPSHOT
18.27.2 REVENUE ANALYSIS
18.27.3 PRODUCT PORTFOLIO
18.27.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST & AFRICA ATAXIA MARKET: PIPELINE ANALYSIS
TABLE 2 MIDDLE EAST & AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 3 MIDDLE EAST & AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 MIDDLE EAST & AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 5 MIDDLE EAST & AFRICA ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 MIDDLE EAST & AFRICA EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 MIDDLE EAST & AFRICA OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 8 MIDDLE EAST & AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 9 MIDDLE EAST & AFRICA TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 10 MIDDLE EAST & AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 11 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 12 MIDDLE EAST & AFRICA STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 13 MIDDLE EAST & AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 14 MIDDLE EAST & AFRICA ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 15 MIDDLE EAST & AFRICA NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 16 MIDDLE EAST & AFRICA ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 17 MIDDLE EAST & AFRICA ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 18 MIDDLE EAST & AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 19 MIDDLE EAST & AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 20 MIDDLE EAST & AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 21 MIDDLE EAST & AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 22 MIDDLE EAST & AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 23 MIDDLE EAST & AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 24 MIDDLE EAST & AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 25 MIDDLE EAST & AFRICA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 26 MIDDLE EAST & AFRICA SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 27 MIDDLE EAST & AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 28 MIDDLE EAST & AFRICA LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 29 MIDDLE EAST & AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 30 MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 MIDDLE EAST & AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 32 MIDDLE EAST & AFRICA ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 MIDDLE EAST & AFRICA PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 34 MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 MIDDLE EAST & AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 36 MIDDLE EAST & AFRICA ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 37 MIDDLE EAST & AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 38 MIDDLE EAST & AFRICA CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 MIDDLE EAST & AFRICA GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 MIDDLE EAST & AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 41 MIDDLE EAST & AFRICA HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 MIDDLE EAST & AFRICA CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 43 MIDDLE EAST & AFRICA HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 44 MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 45 MIDDLE EAST & AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 46 MIDDLE EAST & AFRICA DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 47 MIDDLE EAST & AFRICA RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 MIDDLE EAST & AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 49 MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 77 SOUTH AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 78 SOUTH AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 79 SOUTH AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 80 SOUTH AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 81 SOUTH AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 82 SOUTH AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 83 SOUTH AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 84 SOUTH AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 85 SOUTH AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 86 SOUTH AFRICA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 87 SOUTH AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 88 SOUTH AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 89 SOUTH AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 90 SOUTH AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 91 SOUTH AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 92 SOUTH AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 93 SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 94 SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 95 SOUTH AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 96 SOUTH AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 97 SOUTH AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 98 SOUTH AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 99 SOUTH AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 100 SOUTH AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 101 SOUTH AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 102 SOUTH AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 103 SAUDI ARABIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 104 SAUDI ARABIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 105 SAUDI ARABIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 106 SAUDI ARABIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 107 SAUDI ARABIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 108 SAUDI ARABIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 109 SAUDI ARABIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 110 SAUDI ARABIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 111 SAUDI ARABIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 112 SAUDI ARABIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 113 SAUDI ARABIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 114 SAUDI ARABIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 115 SAUDI ARABIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 116 SAUDI ARABIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 117 SAUDI ARABIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 118 SAUDI ARABIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 119 SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 120 SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 121 SAUDI ARABIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 122 SAUDI ARABIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 123 SAUDI ARABIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 124 SAUDI ARABIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 125 SAUDI ARABIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 126 SAUDI ARABIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 127 SAUDI ARABIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 128 SAUDI ARABIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 129 U.A.E ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 130 U.A.E SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 131 U.A.E ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 132 U.A.E TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 133 U.A.E PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 134 U.A.E STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 135 U.A.E GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 136 U.A.E ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 137 U.A.E NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 138 U.A.E ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 139 U.A.E ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 140 U.A.E ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 141 U.A.E SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 142 U.A.E LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 143 U.A.E SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 144 U.A.E DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 145 U.A.E IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 146 U.A.E IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 147 U.A.E SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 148 U.A.E LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 149 U.A.E ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 150 U.A.E ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 151 U.A.E ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 152 U.A.E ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 153 U.A.E ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 154 U.A.E RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 155 ISRAEL ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 156 ISRAEL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 157 ISRAEL ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 158 ISRAEL TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 159 ISRAEL PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 160 ISRAEL STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 161 ISRAEL GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 162 ISRAEL ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 163 ISRAEL NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 164 ISRAEL ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 165 ISRAEL ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 166 ISRAEL ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 167 ISRAEL SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 168 ISRAEL LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 169 ISRAEL SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 170 ISRAEL DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 171 ISRAEL IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 172 ISRAEL IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 173 ISRAEL SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 174 ISRAEL LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 175 ISRAEL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 176 ISRAEL ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 177 ISRAEL ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 178 ISRAEL ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 179 ISRAEL ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 180 ISRAEL RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 181 EGYPT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 182 EGYPT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 183 EGYPT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 184 EGYPT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 185 EGYPT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 186 EGYPT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 187 EGYPT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 188 EGYPT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 189 EGYPT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 190 EGYPT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 191 EGYPT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 192 EGYPT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 193 EGYPT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 194 EGYPT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 195 EGYPT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 196 EGYPT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 197 EGYPT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 198 EGYPT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 199 EGYPT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 200 EGYPT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 201 EGYPT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 202 EGYPT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 203 EGYPT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 204 EGYPT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 205 EGYPT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 206 EGYPT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 207 KUWAIT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 208 KUWAIT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 209 KUWAIT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 210 KUWAIT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 211 KUWAIT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 212 KUWAIT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 213 KUWAIT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 214 KUWAIT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 215 KUWAIT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 216 KUWAIT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 217 KUWAIT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 218 KUWAIT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 219 KUWAIT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 220 KUWAIT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 221 KUWAIT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 222 KUWAIT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 223 KUWAIT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 224 KUWAIT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 225 KUWAIT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 226 KUWAIT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 227 KUWAIT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 228 KUWAIT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 229 KUWAIT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 230 KUWAIT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 231 KUWAIT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 232 KUWAIT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 233 REST OF MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA ATAXIA MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA ATAXIA MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA ATAXIA MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA ATAXIA MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA ATAXIA MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA ATAXIA MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA ATAXIA MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA ATAXIA MARKET: END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA ATAXIA MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA ATAXIA MARKET: SEGMENTATION
FIGURE 11 RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA ATAXIA MARKET IN THE FORECAST PERIOD
FIGURE 12 SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ATAXIA MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA ATAXIA MARKET
FIGURE 15 MIDDLE EAST & AFRICA ATAXIA MARKET: BY TYPE, 2021
FIGURE 16 MIDDLE EAST & AFRICA ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND)
FIGURE 17 MIDDLE EAST & AFRICA ATAXIA MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 MIDDLE EAST & AFRICA ATAXIA MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PRODUCT, 2021
FIGURE 20 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND)
FIGURE 21 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 22 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DOSAGE FORM, 2021
FIGURE 24 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)
FIGURE 25 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 28 MIDDLE EAST & AFRICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)
FIGURE 29 MIDDLE EAST & AFRICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PATIENT TYPE, 2021
FIGURE 32 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)
FIGURE 33 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA ATAXIA MARKET: BY END USER, 2021
FIGURE 36 MIDDLE EAST & AFRICA ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 37 MIDDLE EAST & AFRICA ATAXIA MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA ATAXIA MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 41 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA ATAXIA MARKET: SNAPSHOT (2021)
FIGURE 44 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2021)
FIGURE 45 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY TYPE (2022-2029)
FIGURE 48 MIDDLE EAST & AFRICA ATAXIA MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
